All Curated Mutation Sites in HPV 
Back to Mutation Home

 The Virus Mutation(VM) module provides researchers the annotations of reported pathogenic mutations in HPV related to human diseases. The curated VM information includes mutation site, mutation level, virus gene/protein/region, virus-associated disease, genotype/subtype, literature evidence, etc.


Browse Data by Virus Gene/Protein/Region, Disease OR Description
*Please select one option you are interested in, the page will be automatically redirected.
     
     

Click the button below to quickly view the viral genes/regions/protein for mutation

Show All
  
E1
  
E1^E4
  
E2
  
E5
  
E6
  
E7
  
L1
  
L2
  

Keyword: Uterine Cervical Neoplasms-32308546
ID PMID Mutation Gene/Protein/Region Encoding Gene/Protein Disease Description Detail
1 32308546 A49C
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
2 32308546 C13T
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
3 32308546 T24C
E6
E6
Uterine Cervical Neoplasms
G
R
L
View
4 32308546 A7167G
LCR
Uterine Cervical Neoplasms
G
R
L
View
5 32308546 A7173C
LCR
Uterine Cervical Neoplasms
G
R
L
View
6 32308546 A7232C
LCR
Uterine Cervical Neoplasms
G
R
L
View
7 32308546 A7338T
LCR
Uterine Cervical Neoplasms
G
R
L
View
8 32308546 A7418G
LCR
Uterine Cervical Neoplasms
G
R
L
View
9 32308546 A7451C
LCR
Uterine Cervical Neoplasms
G
R
L
View
10 32308546 A7484C
LCR
Uterine Cervical Neoplasms
G
R
L
View
11 32308546 A7659G
LCR
Uterine Cervical Neoplasms
G
R
L
View
12 32308546 A7728C
LCR
Uterine Cervical Neoplasms
G
R
L
View
13 32308546 A7829C
LCR
Uterine Cervical Neoplasms
G
R
L
View
14 32308546 A7841G
LCR
Uterine Cervical Neoplasms
G
R
L
View
15 32308546 A7872G
LCR
Uterine Cervical Neoplasms
G
R
L
View
16 32308546 C7174A
LCR
Uterine Cervical Neoplasms
G
R
L
View
17 32308546 C7176T
LCR
Uterine Cervical Neoplasms
G
R
L
View
18 32308546 C7200T
LCR
Uterine Cervical Neoplasms
G
R
L
View
19 32308546 C7286A
LCR
Uterine Cervical Neoplasms
G
R
L
View
20 32308546 C7288A
LCR
Uterine Cervical Neoplasms
G
R
L
View
21 32308546 C7309T
LCR
Uterine Cervical Neoplasms
G
R
L
View
22 32308546 C7393T
LCR
Uterine Cervical Neoplasms
G
R
L
View
23 32308546 C7394T
LCR
Uterine Cervical Neoplasms
G
R
L
View
24 32308546 C7613A
LCR
Uterine Cervical Neoplasms
G
R
L
View
25 32308546 C7668T
LCR
Uterine Cervical Neoplasms
G
R
L
View
26 32308546 C7688A
LCR
Uterine Cervical Neoplasms
G
R
L
View
27 32308546 C7729A
LCR
Uterine Cervical Neoplasms
G
R
L
View
28 32308546 C7763T
LCR
Uterine Cervical Neoplasms
G
R
L
View
29 32308546 C7780T
LCR
Uterine Cervical Neoplasms
G
R
L
View
30 32308546 C7785T
LCR
Uterine Cervical Neoplasms
G
R
L
View
31 32308546 C7873G
LCR
Uterine Cervical Neoplasms
G
R
L
View
32 32308546 C7885G
LCR
Uterine Cervical Neoplasms
G
R
L
View
33 32308546 G7428A
LCR
Uterine Cervical Neoplasms
G
R
L
View
34 32308546 G7435T
LCR
Uterine Cervical Neoplasms
G
R
L
View
35 32308546 G7488A
LCR
Uterine Cervical Neoplasms
G
R
L
View
36 32308546 G7701A
LCR
Uterine Cervical Neoplasms
G
R
L
View
37 32308546 G7825A
LCR
Uterine Cervical Neoplasms
G
R
L
View
38 32308546 G7867A
LCR
Uterine Cervical Neoplasms
G
R
L
View
39 32308546 T7175G
LCR
Uterine Cervical Neoplasms
G
R
L
View
40 32308546 T7269C
LCR
Uterine Cervical Neoplasms
G
R
L
View
41 32308546 T7301G
LCR
Uterine Cervical Neoplasms
G
R
L
View
42 32308546 T7379C
LCR
Uterine Cervical Neoplasms
G
R
L
View
43 32308546 T7699C
LCR
Uterine Cervical Neoplasms
G
R
L
View
44 32308546 T7713G
LCR
Uterine Cervical Neoplasms
G
R
L
View
45 32308546 T7742G
LCR
Uterine Cervical Neoplasms
G
R
L
View
Contents
Description

The table shows all curated mutation sites of HPV in each literature

Table Description Column Note
D
The study mentioned a certain treatment method, such as drug resistance caused by mutations.
G
The study mentioned the virus genotype/subtype information.
R
The study mentioned the reference sequence used for comparison, or the original strain of the virus used for site-directed mutagenesis.
S
The study provided sequence information or accession numbers.
L
The study provided the geographic region/country of data origin.
C
The study provided clinical baseline information.
I
The study involved information related to immune.
T
The study involved host target genes.